# LGR5

Source: https://onco.cc/targets/lgr5-gene/  
OnCo record `lgr5-gene` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.

## Summary

Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. In contrast to classical G protein-coupled receptors, does not activate heterotrimeric G proteins to transduce the signal.

CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Fluorouracil. In OnCo, 1 product record names it (Petosemtamab).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: leucine rich repeat containing G protein-coupled receptor 5; Leucine-rich repeat-containing G protein-coupled receptor 5; HG38; GPR67; GPR49
- Tags: cancer-genes-wave
- Symbol: LGR5
- Class: surface-antigen
- Biology: Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. In contrast to classical G protein-coupled receptors, does not activate heterotrimeric G proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development. Location: Cell membrane; Golgi apparatus, trans-Golgi network membrane (UniProt). Locus 12q21.1 (HGNC).
- Where found: Colorectal cancer: CIViC evidence names this disease; Sarcomas: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 3 clinical evidence items on its variants; a membrane or secreted protein (UniProt keywords) that 1 antibody-based OnCo product name. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Oral Squamous Cell Carcinoma.

## Sources

- HGNC HGNC:4504: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4504
- UniProt O75473: https://www.uniprot.org/uniprotkb/O75473/entry
- NCBI Gene 8549: https://www.ncbi.nlm.nih.gov/gene/8549
- Ensembl ENSG00000139292: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139292

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [Petosemtamab](https://onco.cc/drugs/petosemtamab/)
- pathways: [Wnt / β-catenin](https://onco.cc/pathways/wnt/)
- trials: [A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05759728/)

---
JSON: https://onco.cc/api/v1/entities/lgr5-gene.json